A Phase 1 interventional study of Treatment A and Treatment B in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of the study is to compare the Pharmacokinetics (PK), safety and tolerability of different manufacturing batches of M2951 tablet formulation relative to a reference batch under fasted conditions in healthy participants.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants positive for
Participants with clinically relevant findings (excluding minor, not clinically relevant excursions from normal ranges, as judged by the Investigator) at Screening in biochemistry, hematology, coagulation, and urinalysis examinations for the age of the participant, as judged by the Investigator:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single oral dose of Treatment A on Day 1 in period 1, followed by single oral dose of Treatment B on Day 3 in period 2, followed by Treatment C on Day 5 in period 3 and followed by single oral dose of Treatment D on Day 7 under fasted condition in period 4. There will be 48 hours washout period between each treatment period.
Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D
Participants will receive single oral dose of Treatment B on Day 1 in period 1, followed by single oral dose of Treatment D on Day 3 in period 2, followed by Treatment A on Day 5 in period 3 and followed by single oral dose of Treatment C on Day 7 under fasted condition in period 4. There will be 48 hours washout period between each treatment period.
Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D
Participants will receive single oral dose of Treatment C on Day 1 in period 1, followed by single oral dose of Treatment A on Day 3 in period 2, followed by Treatment D on Day 5 in period 3 and followed by single oral dose of Treatment B on Day 7 under fasted condition in period 4. There will be 48 hours washout period between each treatment period.
Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D
Participants will receive single oral dose of Treatment D on Day 1 in period 1, followed by single oral dose of Treatment C on Day 3 in period 2, followed by Treatment B on Day 5 in period 3 and followed by single oral dose of Treatment A on Day 7 under fasted condition in period 4. There will be 48 hours washout period between each treatment period.
Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D
Participants will receive single dose of Treatment A in treatment period 1, 2, 3 or 4 under fasted conditions.
Also known as: Evobrutinib
Participants will receive single dose of Treatment B in treatment period 1, 2, 3 or 4 under fasted conditions.
Also known as: Evobrutinib
Participants will receive single dose of Treatment C in treatment period 1, 2, 3 or 4 under fasted conditions.
Also known as: Evobrutinib
Participants will receive single dose of Treatment D in treatment period 1, 2, 3 or 4 under fasted conditions.
Also known as: Evobrutinib
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib
Cmax was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs.
Time frame: Up to 34 days
Number of Participants With Treatment- Emergent Adverse Events (TEAEs) by Severity
The Investigator assessed the severity of each AE and SAE reported during the study and assign it to one of the following categories: Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities; Severe: An event that prevents normal everyday activities. Do not confuse an AE that is assessed as severe with a SAE. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe.
Time frame: Up to 34 days
Change From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure
Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
Time frame: Baseline (Pre-dose), 2 hours post-dose
Change From Baseline in Vital Signs: Temperature
Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
Time frame: Baseline (Pre-dose), 2 hours post-dose
Change From Baseline in Vital Signs: Pulse Rate
Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
Time frame: Baseline (Pre-dose), 2 hours post-dose
Change From Baseline in Vital Signs: Respiratory Rate
Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
Time frame: Baseline (Pre-dose), 2 hours post-dose
Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate
Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions
Time frame: Baseline (Pre-dose), 2 hours post-dose
Change From Baseline in Electrocardiograms (ECGs) Parameter: RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration
RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
Time frame: Baseline (Pre-dose), 2 hours post-dose
Number of Participants With Clinically Significant Changes in Laboratory Parameters
Laboratory investigation included hematology, biochemistry and urinalysis. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. Clinical significance was determined by the investigator.
Time frame: Screening up to Day 8
Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Evobrutinib
The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification (LLOQ). Calculated using the mixed log-linear trapezoidal rule (linear up, log down).
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Evobrutinib
Time to reach the maximum observed plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Terminal Half Life (T1/2) of Evobrutinib
Terminal half-life was calculated as log2 divided by lambda z. Lambda z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Apparent Total Body Clearance (CL/f) of Evobrutinib
Apparent total body clearance of drug from plasma following extravascular administration, calculated as dose/AUC0-infinity for Evobrutinib.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Apparent Volume of Distribution During Terminal Phase (VZ/f) of Evobrutinib
Vz/f is defined as the apparent volume of distribution during the terminal phase following extravascular administration for Evobrutinib.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Evobrutinib (Treatment B, C and D) Compared to Evobrutinib Reference Treatment A
Relative Bioavailability in percentage of each treatment (B, C, and D) in relation to the reference Treatment (A) was calculated as Frel = 100 multiplied by (AUC0-inf \[treatment B, C, D\]) multiplied by Dose \[treatment A\] divided by (AUC0-inf \[treatment A\]) multiplied by Dose \[treatment B, C, D\]. Treatment A to determine relative bioavailability.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
| Milestone | Sequence 1: Treatment A-B-C-D | Sequence 2: Treatment B-D-A-C | Sequence 3: Treatment C-A-D-B | Sequence 4: Treatment D-C-B-A |
|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 |
| Completed | 7 | 6 | 6 | 7 |
| Not completed | 0 | 1 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Dropped out on day 5; private reasons | 0 | 1 | 0 | 0 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
| hour×nanogram per milliliter (h×ng/mL) | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib | 198 ± 44.0 | 164 ± 45.1 | 207 ± 44.6 | 205 ± 38.3 |
Cmax was obtained directly from the concentration versus time curve.
| nanogram per milliliter (ng/mL) | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Evobrutinib | 111 ± 69.9 | 84.5 ± 71.9 | 117 ± 62.6 | 121 ± 64.7 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs.
| Participants | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Number of Participants With Treatment- Emergent Adverse Events (TEAEs) | 2 | 1 | 2 | 5 |
The Investigator assessed the severity of each AE and SAE reported during the study and assign it to one of the following categories: Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities; Severe: An event that prevents normal everyday activities. Do not confuse an AE that is assessed as severe with a SAE. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe.
| Participants | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Mild | 2 | 0 | 0 | 4 |
| Moderate | 0 | 1 | 1 | 1 |
| Severe | 0 | 0 | 1 | 0 |
Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
| millimeters of mercury (mmHg) | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Systolic Blood Pressure | 0 ± 10.4 | -1 ± 7.3 | -1 ± 6.9 | -1 ± 7.0 |
| Diastolic Blood Pressure | -1 ± 5.8 | -1 ± 5.8 | 0 ± 6.0 | -1 ± 4.7 |
Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
| degree Celsius | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Change From Baseline in Vital Signs: Temperature | 0.2 ± 0.27 | 0.2 ± 0.34 | 0.0 ± 0.24 | 0.0 ± 0.27 |
Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
| beats per minute | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Change From Baseline in Vital Signs: Pulse Rate | -2 ± 8.5 | -1 ± 8.6 | -3 ± 8.3 | -2 ± 7.3 |
Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
| breaths per minute | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Change From Baseline in Vital Signs: Respiratory Rate | 0 ± 2.5 | -1 ± 2.0 | -1 ± 1.9 | -0 ± 2.0 |
Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions
| beats per minute | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate | -4 ± 6.1 | -2 ± 4.0 | -2 ± 6.6 | -1 ± 4.7 |
RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.
| millisecond (msec) | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| RR Duration | 52 ± 84.6 | 36 ± 61.3 | 44 ± 106.4 | 18 ± 70.3 |
| QT Duration | 9 ± 10.9 | 6 ± 9.8 | 10 ± 10.7 | 4 ± 10.1 |
| QTcF Duration | 1 ± 11.8 | 1 ± 9.5 | 4 ± 8.9 | 2 ± 8.7 |
| PR Duration | -5 ± 7.8 | -1 ± 6.1 | -0 ± 8.0 | 0 ± 5.8 |
| QRS Duration | -0 ± 4.9 | -1 ± 4.9 | 1 ± 4.8 | -1 ± 4.6 |
Laboratory investigation included hematology, biochemistry and urinalysis. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. Clinical significance was determined by the investigator.
| Participants | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Laboratory Parameters | 0 | 0 | 0 | 0 |
The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification (LLOQ). Calculated using the mixed log-linear trapezoidal rule (linear up, log down).
| h×ng/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Evobrutinib | 194 ± 44.5 | 160 ± 46.3 | 204 ± 45.1 | 202 ± 39.2 |
Time to reach the maximum observed plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
| hours | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Evobrutinib | 1.00 (0.500 to 1.50) | 1.00 (0.500 to 2.00) | 1.00 (0.250 to 1.50) | 1.00 (0.500 to 2.00) |
Terminal half-life was calculated as log2 divided by lambda z. Lambda z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve.
| hours | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Terminal Half Life (T1/2) of Evobrutinib | 1.64 (1.01 to 10.8) | 1.78 (1.05 to 13.7) | 1.72 (1.07 to 15.6) | 1.37 (0.982 to 5.41) |
Apparent total body clearance of drug from plasma following extravascular administration, calculated as dose/AUC0-infinity for Evobrutinib.
| Liter per hour | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Apparent Total Body Clearance (CL/f) of Evobrutinib | 227 ± 44.0 | 275 ± 45.1 | 217 ± 44.6 | 219 ± 38.3 |
Vz/f is defined as the apparent volume of distribution during the terminal phase following extravascular administration for Evobrutinib.
| Liters | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Apparent Volume of Distribution During Terminal Phase (VZ/f) of Evobrutinib | 627 ± 84.1 | 843 ± 111.4 | 658 ± 89.2 | 522 ± 74.2 |
Relative Bioavailability in percentage of each treatment (B, C, and D) in relation to the reference Treatment (A) was calculated as Frel = 100 multiplied by (AUC0-inf \[treatment B, C, D\]) multiplied by Dose \[treatment A\] divided by (AUC0-inf \[treatment A\]) multiplied by Dose \[treatment B, C, D\]. Treatment A to determine relative bioavailability.
| percentage bioavailability | Treatment B | Treatment C | Treatment D |
|---|---|---|---|
| Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Evobrutinib (Treatment B, C and D) Compared to Evobrutinib Reference Treatment A | 84.0 (75.8 to 93.1) | 105 (98.1 to 112) | 106 (98.0 to 115) |
Collected over Up to 34 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/26 (0%) | 0/26 (0%) | 2/26 (7.7%) |
| Treatment B | 0/27 (0%) | 0/27 (0%) | 1/27 (3.7%) |
| Treatment C | 0/27 (0%) | 1/27 (3.7%) | 1/27 (3.7%) |
| Treatment D | 0/27 (0%) | 0/27 (0%) | 5/27 (18.5%) |
| Event | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| SeizureNervous system disorders | 0/26 | 0/27 | 1/27 | 0/27 |
| Event | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| HeadacheNervous system disorders | 0/26 | 0/27 | 1/27 | 2/27 |
| NasopharyngitisInfections and infestations | 1/26 | 0/27 | 0/27 | 1/27 |
| DizzinessNervous system disorders | 1/26 | 0/27 | 0/27 | 1/27 |
| HypersensitivityImmune system disorders | 0/26 | 0/27 | 0/27 | 1/27 |
| Lipase increasedInvestigations | 0/26 | 1/27 | 0/27 | 0/27 |
| Age, Continuous(Years) | Sequence 1: Treatment A-B-C-D | Sequence 2: Treatment B-D-A-C | Sequence 3: Treatment C-A-D-B | Sequence 4: Treatment D-C-B-A | Total |
|---|---|---|---|---|---|
| Mean | 30 ± 5.6 | 37 ± 10.1 | 37 ± 12.8 | 35 ± 10.4 | 35 ± 9.9 |
| Sex: Female, Male(Participants) | Sequence 1: Treatment A-B-C-D | Sequence 2: Treatment B-D-A-C | Sequence 3: Treatment C-A-D-B | Sequence 4: Treatment D-C-B-A | Total |
|---|---|---|---|---|---|
| Female | 4 | 5 | 3 | 5 | 17 |
| Male | 3 | 2 | 4 | 2 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Sequence 1: Treatment A-B-C-D | Sequence 2: Treatment B-D-A-C | Sequence 3: Treatment C-A-D-B | Sequence 4: Treatment D-C-B-A | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 7 | 6 | 7 | 7 | 27 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence 1: Treatment A-B-C-D | Sequence 2: Treatment B-D-A-C | Sequence 3: Treatment C-A-D-B | Sequence 4: Treatment D-C-B-A | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 7 | 7 | 7 | 7 | 28 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Ran from Jan 2023 to primary completion in Feb 2023, 1 month.
Results were first posted in Dec 2025, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evobrutinib
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany →